Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
April 16 2021 - 7:05AM
Business Wire
Virios Therapeutics, Inc. (Nasdaq: VIRI), a
clinical-stage biotechnology company focused on advancing novel
antiviral therapies to treat diseases associated with virally
triggered or maintained immune responses, today announced an
interview with Chairman and CEO, Greg Duncan, will air on The
RedChip Money Report on the Bloomberg Network in the U.S. on
Saturday, April 17, 2021 at 7 p.m. Eastern Time across the United
States. The RedChip Money Report airs on Bloomberg Television U.S.
on Saturdays at 7 p.m. Eastern Time in 73 million homes.
To view the interview segment, please visit:
https://youtu.be/9M0B8RPahYs
“The RedChip Money Report" delivers insightful commentary on
small-cap investing, interviews with Wall Street analysts,
financial book reviews, as well as featured interviews with
executives of public companies.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage
biotechnology company focused on advancing novel, dual mechanism
antiviral therapies to treat conditions associated with virally
triggered or maintained immune responses, such as fibromyalgia
(“FM”). Immune responses related to the activation of tissue
resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a
potential root cause triggering and/or sustaining chronic illnesses
such as FM, irritable bowel disease (“IBS”), chronic fatigue
syndrome and other functional somatic syndromes, all of which are
characterized by waxing and waning symptoms with no obvious
etiology. Our lead development candidate (“IMC-1”) is a novel,
proprietary, fixed dose combination of famciclovir and celecoxib
designed to synergistically suppress HSV-1 replication, with the
end goal of reducing virally promoted disease symptoms.
Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome
measures was previously demonstrated in a Phase 2 clinical trial.
These trial results are suggestive that IMC-1 may represent a new
and novel treatment for fibromyalgia. IMC-1 has been granted fast
track designation by the FDA and is currently being tested in a
multi-center, randomized, double-blind, placebo-controlled Phase 2B
trial (“FORTRESS”) designed to set the stage for registrational
studies. The company is led by an executive team highly experienced
in the successful development and commercialization of novel
therapies. For more information, please visit www.virios.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Virios Therapeutics’ current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. These and other risks and uncertainties
are described more fully in the section titled “Risk Factors” in
the Annual Report on Form 10-K for the year ended December 31, 2020
filed with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update
such information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210416005036/en/
Investor Relations Contact: Dave Gentry RedChip Companies Inc.
407-491-4498 dave@redchip.com
Company Contact: Jenny Kobin IR@Virios.com
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Apr 2023 to Apr 2024